ĀÜĄņĀŅĀ×

CD

Chris Dougherty

Board Observer at Arrivo BioVentures

Chris is the Head of Corporate Development at Jazz Pharmaceuticals, where he has been a member of the Corporate Development team since 2012 and has worked on over $10B in total transactions across neuroscience and oncology during his time there. Prior to Jazz, he worked in a variety of operational roles at Azur Pharma and started his career at Deloitte, focused on life science and non-profit clients. Chris holds a bachelorā€™s degrees in accounting and finance from The Ohio State University.